Alzheimer’s Disease Medication

If Alzheimer’s disease were a house fire, medication wouldn’t be the fire extinguisher that magically
puts everything out. It’s more like a set of tools that can slow down some damage, reduce symptoms,
and help everyone in the house function a little better while the firefighters (researchers) keep
working on the bigger solution.

Today, Alzheimer’s disease medication falls into two main buckets:
(1) symptom-managing drugs that can help with memory, thinking, and daily function for a time,
and (2) disease-modifying therapies that target Alzheimer’s biology (most notably amyloid)
and can slow clinical decline in carefully selected people with early-stage disease.
There are also medications aimed at behavioral and psychological symptoms (like agitation),
which can be as challenging for families as memory loss itself.

First, a quick reality check (the helpful kind)

Alzheimer’s medications don’t work the same way for everyone. Some people feel a noticeable boost
in attention or day-to-day function; others experience subtle changes that are easier for caregivers
to spot than the person taking the drug. And sometimes the best “result” is simply a slower slide,
fewer crises, and more good days stacked together.

The best outcomes usually come from combining medication with non-drug supportsstructured routines,
caregiver training, safer home setup, physical activity, sleep and hearing/vision carebecause Alzheimer’s
is never “just memory.” It’s the whole system.

How doctors match medication to Alzheimer’s stages

Alzheimer’s is often described along a spectrum:
mild cognitive impairment (MCI) due to Alzheimer’s, then mild dementia,
moderate dementia, and severe dementia. Medication choices and goals
change across these stages.

• Early stage (MCI or mild dementia): consider symptom drugs, and in eligible patients, disease-modifying anti-amyloid therapy.
• Moderate stage: symptom drugs may still help; focus expands to function, behavior, safety, caregiver support.
• Severe stage: prioritize comfort, safety, sleep, pain control, and reducing distressing behaviors.

Bucket #1: Medications that treat symptoms (memory and thinking)

These are sometimes called “cognitive enhancers,” but a more honest label is:
“medications that may help the brain communicate a bit better, for a while.”
They do not stop the underlying disease process, but they can support thinking, attention, and daily
functioning in some people.

Cholinesterase inhibitors (for mild to moderate Alzheimer’s symptoms)

Cholinesterase inhibitors work by increasing the availability of acetylcholine, a brain chemical
involved in memory and learning. In Alzheimer’s, acetylcholine activity tends to dropso these drugs
aim to boost what’s left.

Common cholinesterase inhibitors include:

• Donepezil (often used across mild to severe stages, depending on the person)
• Rivastigmine (available as a pill and a skin patch)
• Galantamine
• Benzgalantamine (a newer option approved for mild to moderate dementia of the Alzheimer’s type)

What benefits look like: A person may be a little more engaged, follow conversations
better, track routines more easily, or show fewer “blank” moments. Sometimes families notice
improvements in motivation or day-to-day smoothness more than test-score changes.

Common side effects:

• Upset stomach (nausea, vomiting, diarrhea)
• Loss of appetite or weight loss
• Vivid dreams or sleep disruption (especially with donepezil in some people)
• Slow heart rate, dizziness, fainting, or falls (particularly in people with certain heart conditions)

Practical tip: If stomach side effects are an issue, clinicians may suggest slower
dose increases, taking medication with food (when appropriate), or switching formslike using a
rivastigmine patch instead of pills. Small tweaks can make a big difference in
whether someone can stay on therapy.

Memantine (for moderate to severe Alzheimer’s symptoms)

Memantine works differently: it regulates glutamate signaling through NMDA receptors. Glutamate is
crucial for learning and memory, but too much activity can contribute to nerve-cell stress. Memantine
is used to support thinking and function in moderate to severe Alzheimer’s, sometimes improving
day-to-day abilities like dressing, eating, or handling familiar tasks with less frustration.

Common side effects may include: dizziness, headache, constipation, and confusion.

Combination therapy (donepezil + memantine)

Some people take a combination approach (either as separate medications or a combined product).
The goal is simple: support multiple brain signaling pathways at the same timeespecially when the
disease has moved into the moderate stage.

Bucket #2: Disease-modifying therapies (targeting amyloid in early Alzheimer’s)

Here’s where Alzheimer’s medication has changed most in recent years. Disease-modifying therapies
are designed to target Alzheimer’s biologyespecially amyloid plaquesrather than only managing
symptoms.

In the U.S., two anti-amyloid monoclonal antibody therapies have received traditional FDA approval
for Alzheimer’s disease and are used in the early symptomatic stages
(mild cognitive impairment due to Alzheimer’s or mild Alzheimer’s dementia).
They are given by intravenous infusion and require careful monitoring.

Leqembi (lecanemab)

Leqembi is an amyloid beta-directed antibody. It’s intended for people in the early stages of
Alzheimer’s who have confirmed amyloid pathology. In clinical trials, it slowed clinical decline
compared with placebobut it is not a cure, and the benefit is best described as “slowing the slope,”
not reversing symptoms.

Key considerations:

• Who it’s for: mild cognitive impairment due to Alzheimer’s or mild Alzheimer’s dementia with evidence of amyloid.
• How it’s given: IV infusion on a repeating schedule, typically through an infusion center.
• Monitoring: MRI scans before and during treatment to watch for ARIA (see below).

Kisunla (donanemab)

Kisunla is another anti-amyloid antibody approved for Alzheimer’s disease, with treatment initiated
in people with mild cognitive impairment or mild dementia stage, the population studied in trials.
It is administered by IV infusion every four weeks and similarly requires safety monitoring.

Key considerations:

• Who it’s for: early symptomatic Alzheimer’s with confirmed Alzheimer-type pathology (as determined by the treating team’s evaluation and testing).
• How it’s given: monthly IV infusion.
• Monitoring: MRI scans and clinical checks for side effects, especially early in therapy.

What is ARIAand why does everyone keep talking about it?

ARIA stands for amyloid-related imaging abnormalities. It’s a safety issue seen with
anti-amyloid antibodies and is detected on MRI. There are two main types:
ARIA-E (swelling/edema) and ARIA-H (small bleeds/microhemorrhages or
superficial siderosis).

Many cases are asymptomatic and found only on scheduled MRIs. When symptoms happen, they may include
headache, confusion, dizziness, vision changes, nausea, or new neurological symptoms. ARIA can be
serious, which is why these therapies require monitoring and why patient selection matters.

Risk factors and “extra caution” situations often include:

• Carrying certain APOE ε4 genetic risk variants (especially higher-risk profiles)
• History of brain bleeds or MRI findings that increase bleeding risk
• Use of blood thinners or other medications that may increase bleeding risk (case-by-case medical decision)
• Inability to get MRI scans (for example, due to certain implants or severe claustrophobia without solutions)

The big takeaway: Disease-modifying therapy is a shared decision that weighs potential
benefit against risk, monitoring burden, cost, and the person’s values.

Aduhelm (aducanumab): a note on a discontinued therapy

Aduhelm was the first anti-amyloid antibody approved in the U.S. under accelerated approval, but it
was later discontinued by its manufacturer and its accelerated approval indication was withdrawn.
The current anti-amyloid landscape has shifted toward therapies with traditional approval and clearer
clinical-trial confirmation of benefit.

Medications for agitation and other behavioral symptoms

Alzheimer’s isn’t only memory loss. Many families struggle more with changes in mood and behavior:
agitation, aggression, sleep disruption, depression, anxiety, hallucinations, or wandering.
Medication can helpbut it should rarely be the first move.

Non-drug strategies come first (because they actually work)

Before adding a pill, clinicians often look for triggers: pain, constipation, urinary tract infection,
dehydration, poor sleep, medication side effects, overstimulation, loneliness, or caregiver approach.
Fixing the trigger can reduce agitation more effectively than sedating someone.

Rexulti (brexpiprazole) for agitation associated with dementia due to Alzheimer’s disease

Rexulti is FDA-approved for agitation associated with dementia due to Alzheimer’s disease.
That matters because agitation can be dangerous and exhausting, and historically families have relied
on off-label options with significant risks.

Rexulti (like other antipsychotics) carries a boxed warning about increased mortality risk in elderly
patients with dementia-related psychosis. In practice, that means prescribers aim for:
the lowest effective dose, frequent reassessment, and a clear plan to stop or reduce if possible.

Other commonly used (often off-label) medication categories

• Antidepressants (SSRIs): sometimes used for depression, anxiety, or irritability.
• Sleep supports: chosen carefully; many sedatives can worsen confusion or increase fall risk.
• Short-term calming medications: sometimes used in crises, but with careful monitoring.

Because older adults are more vulnerable to side effects (falls, sedation, worsening confusion),
clinicians usually prefer “start low, go slow” and revisit whether the medicine is helping in real life,
not just on paper.

A practical medication roadmap (what a good plan looks like)

Step 1: Confirm what you’re treating

“Memory problems” can come from many sources: thyroid issues, vitamin deficiencies, medication side effects,
sleep apnea, depression, hearing loss, or other dementias. A thorough evaluation helps avoid treating
the wrong problem with the wrong medication.

Step 2: Match the drug to the stage and the goal

• Goal: improve cognition/attention (mild–moderate): consider cholinesterase inhibitors.
• Goal: support function (moderate–severe): consider memantine, sometimes in combination.
• Goal: slow early decline (MCI/mild dementia + amyloid confirmed): consider anti-amyloid therapy if eligible.
• Goal: reduce agitation/distress: prioritize non-drug steps, then consider targeted medication if needed.

Step 3: Track benefits like a scientist (without ruining dinner)

Medication “success” can be subtle. Consider tracking a few real-life metrics for 4–12 weeks after a change:

• Is morning routine smoother?
• Is conversation easier?
• Are there fewer unsafe moments (wandering, stove incidents)?
• Is sleep more consistent?
• Is agitation less frequent or less intense?

Step 4: Watch for side effects and interactions

Alzheimer’s often comes with other medical conditions, which means multiple medications. A pharmacist
or clinician medication review can uncover problems like dizziness-causing combos, anticholinergic
medications that worsen thinking, or duplicate sedatives.

Questions to ask your clinician (so you leave with clarity)

• What stage of Alzheimer’s are we treatingand what’s the goal for medication right now?
• Which benefits should we realistically expect, and how soon?
• What side effects should prompt a call, an urgent visit, or an ER trip?
• Are there medications on the current list that may worsen confusion or increase fall risk?
• If considering anti-amyloid therapy: what testing confirms eligibility, what is the MRI plan, and what risks apply to us?
• How will we reassess in 1–3 months to decide whether to continue, adjust, or stop?

Bottom line

Alzheimer’s disease medication is no longer a one-lane road. Symptom medications can still matter
especially when they make daily life feel more manageable. Meanwhile, disease-modifying anti-amyloid
therapies have created a new option for eligible people with early Alzheimer’s, though they come with
monitoring demands and meaningful risks that require shared decision-making.

The most effective “treatment plan” is rarely a single drug. It’s a coordinated strategy: the right
medication (when appropriate), the right supports, and the right expectationsplus a caregiver who
gets support too, because Alzheimer’s is a team sport and nobody should have to play it alone.

Real-world experiences with Alzheimer’s disease medication (what it can feel like)

Real life with Alzheimer’s medication rarely looks like a movie montage where someone takes a pill
and suddenly remembers everyone’s birthdays. It looks more like small wins, careful tradeoffs, and
a lot of “let’s see how this goes” conversationsusually followed by a caregiver holding a notebook
(or a phone app) like they’re running a tiny clinical trial at home.

Families often describe the first symptom medicationlike donepezil or rivastigmineas a moment of
cautious hope. Not because anyone expects a cure, but because doing something feels better
than watching and waiting. Early on, a “good response” might be that the person can follow a TV show
a bit longer, participate in dinner conversation more consistently, or need fewer reminders to do
familiar tasks. One caregiver might say, “He’s still forgetful, but he’s less lost.” That’s a real
outcome.

Side effects are a frequent plot twist. Nausea and appetite changes can be frustrating because they
collide with another Alzheimer’s challenge: maintaining good nutrition. Some people do fine after a
slow dose increase, while others need a switchlike moving from a pill to a rivastigmine patch. The
patch can feel like a relief: fewer stomach complaints, less daily negotiation, and one less thing
to “remember to remember.” Of course, then you may be negotiating with the patch instead (“Why is
this sticker still on me?”), so nobody gets bored.

When memantine is added later, caregivers often notice changes in function rather than memoryless
frustration during dressing, fewer arguments about steps in a routine, or slightly improved ability
to stay on task. Sometimes it’s not dramatic; it’s more like the volume knob on confusion is turned
down a notch. And sometimes the benefit is that a person seems calmer in the face of change, which
can reduce conflict for everyone.

Disease-modifying therapy (like anti-amyloid infusions) can feel like a whole new job. People talk
about scheduling infusion appointments, arranging transportation, coordinating baseline testing, and
fitting MRI scans into life. For some families, the monitoring feels reassuring“we’re watching this
closely.” For others, it’s stressful and time-consuming. The decision often comes down to values:
How much burden is acceptable for a chance at slowing decline? What risks feel tolerable? What does
“quality of life” mean to this person right now?

And then there’s agitationone of the hardest chapters. Caregivers describe it as heartbreaking,
because the person isn’t being “difficult” on purpose; their brain is struggling to interpret reality.
When non-drug strategies aren’t enough, medication decisions can feel heavy. Families often say the
best clinicians are the ones who explain risks plainly, start with the gentlest effective plan, and
keep reassessingbecause in Alzheimer’s care, “set it and forget it” is basically a fantasy genre.